<DOC>
	<DOCNO>NCT00006047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness nitrocamptothecin plus etoposide treating patient advance solid tumor .</brief_summary>
	<brief_title>Combination Therapy With Oral 9-Nitrocamptothecin &amp; Oral Etoposide</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , dose limit toxicity , safety nitrocamptothecin administer etoposide patient advance solid tumor . II . Determine change expression activity topoisomerase I II occur administration treatment regimen patient . III . Determine plasma pharmacokinetics treatment regimen patient . IV . Compare hematologic nonhematologic toxicity treatment regimen patient 70 year age old versus patient young 70 year age . OUTLINE : This dose escalation study nitrocamptothecin . Patients receive oral nitrocamptothecin day 1-3 oral etoposide day 4-5 week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos nitrocamptothecin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 4 week toxicity resolve . PROJECTED ACCRUAL : Approximately 40-60 patient accrue study 18 24 month .</detailed_description>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<mesh_term>Topoisomerase I Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonhematologic malignancy refractory available therapy curative therapy exist Measurable evaluable disease No active brain metastasis , include evidence cerebral edema CT scan MRI , progression prior image study , requirement steroid clinical symptom of/from brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL ALT AST less 2 time upper limit normal ( ULN ) ( unless clearly relate hepatic metastasis ) Renal : Creatinine le 1.5 time ULN Other : No serious uncontrolled medical disorder active infection would preclude study No dementia alter mental status would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 10 week study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No concurrent colony stimulate factor ( e.g. , filgrastim ( GCSF ) sargramostim ( GMCSF ) ) Chemotherapy : No prior topoisomerase I inhibitor ( e.g. , nitrocamptothecin , aminocamptothecin , irinotecan , topotecan ) At least 4 week since prior chemotherapy ( least 6 week since prior nitrosoureas , mitomycin , carboplatin ) No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 4 week since prior hormonal therapy No concurrent hormonal anticancer therapy Radiotherapy : At least 4 week since prior radiotherapy involve least 30 % bone marrow No concurrent radiotherapy Surgery : Not specify Other : No concurrent experimental anticancer medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>